Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.

cancer
squamous cell carcinoma
metastatic head and neck squamous cell cancer
pd-1 inhibitor
metastatic squamous cell carcinoma
  • 0 views
  • 19 Feb, 2024
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.

adenocarcinoma of prostate
hbed-cc
adenocarcinoma
stereotactic body radiation therapy
metastasis
  • 16 views
  • 19 Feb, 2024
18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.

positron emission tomography
digital rectal examination
multiparametric magnetic resonance imaging
pet/ct scan
  • 0 views
  • 19 Feb, 2024
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

The investigators propose a phase II randomized-controlled study on using durvalumab in combination with induction chemotherapy followed by concurrent chemoradiation and adjuvant durvalumab, compared to induction chemotherapy followed by concurrent chemoradiation for previously untreated locoregionally advanced stage III to IVA NPC. In parallel, the investigators will also perform collateral tumor …

intra-articular injection
prednisone
cancer
adjuvant
durvalumab
  • 0 views
  • 19 Feb, 2024